EMA/193393/2011

European Medicines Agency decision
P/91/2011

of 8 April 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral for propane-1-sulfonic acid \( 3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl \)-amide (RO5185426), (EMEA-000978-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
of 8 April 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral for propane-1-
sulfonic acid \{(3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl)-amide (RO5185426), (EMEA-000978-PIP01-10)\} in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to the application submitted by F. Hoffmann La Roche Ltd on 1 June 2010 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 February 2011, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for propane-1-sulfonic acid \{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl\}-amide (RO5185426), film coated tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for propane-1-sulfonic acid \{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl\}-amide (RO5185426), film coated tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to F. Hoffmann La Roche, Grenzacherstrasse, 4070 – Basel, Switzerland.

Done at London, 8 April 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral
EMEA-000978-PIP01-10

Scope of the application

Active substance(s):
Propane-1-sulfonic acid \{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl\}-amide (RO5185426)

Condition(s):
Treatment of melanoma

Pharmaceutical form(s):
Film Coated Tablets

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
F. Hoffmann La Roche Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, F. Hoffmann La Roche Ltd submitted for agreement to the European Medicines Agency on 1 June 2010 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 15 July 2010.

Supplementary information was provided by the applicant on 6 December 2010. The applicant proposed modifications to the paediatric investigation plan.

The paediatric subset from birth to less than 12 years of age in the condition subject to the application is covered by a class waiver as per EMA decision of 20 December 2010 (P/345/2010).
Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 18 February 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of melanoma

2.1.1. Indication(s) targeted by the PIP

Treatment of unresectable stage IIIC or stage IV melanoma in patients from 12 to less than 18 years old, positive for BRAF V600 mutation.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film Coated Tablets, 120 mg and 240 mg.

2.1.4. Studies

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>1</td>
<td>Study 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of a round shape 120 mg tablet with a maximum diameter below 10.5 mm</td>
</tr>
<tr>
<td>Non-clinical</td>
<td></td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Clinical</td>
<td>1</td>
<td>Study 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Open-label, multicentre, single-arm trial to evaluate the recommended dose, safety, pharmacokinetics and response of RO5185426 in paediatric patients from 12 to less than 18 years old with BRAF V600 mutation positive unresectable stage IIIC or stage IV melanoma.</td>
</tr>
</tbody>
</table>

3. Follow-up, completion and deferral of PIP

| Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use: | No |
| Date of completion of the paediatric investigation plan: | By March 2017 |
| Deferral for one or more studies contained in the paediatric investigation plan: | Yes |